GVS advice cannabidiol (Epidyolex®) as adjuvant treatment for 2 epileptic disorders
The National Health Care Institute has completed its assessment whether the medicinal product cannabidiol (Epidyolex®) can be included in the Medicine Reimbursement System (GVS). This product is indicated as adjuvant treatment in patients aged 2 years and older with therapy-resistant Lennox-Gastaut syndrome (LGS) or therapy-resistant Dravet syndrome (DS). The National Health Care Institute advises the Minister of Health, Welfare and Sport only to include cannabidiol (Epidyolex®) on List 1B of the Medicine Reimbursement System (GVS) after a price reduction is negotiated. In November 2022, the Minister decided to adopt the advice of the National Health Care Institute.
Indication for which reimbursement is requested
Cannabidiol is indicated for use as adjuvant therapy in combination with clobazam for the seizures that are associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients aged 2 years and older.
National Health Care Institute's advice
The National Health Care concludes that cannabidiol (Epidyolex®) can olny be included on List 1B of the Medicine Reimbursement System (GVS) after a price reduction is negotiated.
This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.